Fosamax and Osteonecrosis of the Jaw: Understanding the FDA Warning and Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Awareness

For decades, general health and science communication has served as a foundational pillar for public understanding of medication risks and physiological responses. This legacy context established a baseline awareness that certain pharmaceuticals, while beneficial for primary indications, may carry unintended consequences for specific patient populations. Within this broad framework, the discourse around bisphosphonate therapies—particularly Fosamax—has evolved from general bone health management to a more focused examination of rare but serious adverse events. The transition from this general health heritage to a targeted occupational exposure concern requires a deliberate shift in perspective. While initial warnings centered on patient populations receiving long-term bisphosphonate therapy for conditions like osteoporosis, the risk profile expands when considering individuals who may encounter these compounds through non-therapeutic routes. Occupational exposure scenarios—such as manufacturing, handling, or environmental contact with Fosamax or its precursors—introduce a distinct set of variables that differ from prescribed clinical use. These settings lack the controlled dosing, medical oversight, and patient-specific risk stratification that characterize therapeutic administration. This pivot acknowledges that the same biological pathways implicated in medication-related osteonecrosis of the jaw may be activated through alternative exposure mechanisms. The concern thus moves from a patient-centered risk assessment to an occupational health framework, where duration, concentration, and route of exposure become critical parameters. This reframing preserves the legacy of informed risk communication while extending its principles to populations not traditionally considered in the original FDA warnings.

Bridging to Medical Evidence: Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health communication, the medical evidence establishes a clear link between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation often involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis relies on clinical examination and imaging, with staging systems ranging from "at-risk" to stage 3 based on severity (https://pubmed.ncbi.nlm.nih.gov/40619534/). The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This can impair the jawbone's ability to repair microdamage and respond to local stressors such as dental infections or trauma. Multiscale characterization of jawbone tissue has provided comprehensive information that helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high remodeling rate and susceptibility to bacterial invasion from oral flora make it particularly vulnerable. Additionally, bisphosphonates accumulate in bone matrix and can be released during remodeling, leading to prolonged suppression of bone turnover even after drug discontinuation. Risk factors for developing ONJ while on Fosamax include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

FDA Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the FDA-approved labeling. The label includes a specific section (5.4) on osteonecrosis of the jaw, describing its association with bisphosphonates and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the drug, but a subset may have recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ development, excluding other etiologies such as cancer or radiation therapy, and assessing the presence of known risk factors. The timeline between exposure and documented harm can vary widely, from days to months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients on long-term therapy, the risk may increase with cumulative exposure. Studies have introduced metrics such as equivalent dose (ED) and threshold dose (TD) to predict ONJ risk, with ED standardized to the cumulative dose of four years of weekly oral alendronate use (14,560 mg) (https://pubmed.ncbi.nlm.nih.gov/40619534/). These tools may help clinicians assess individual patient risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the FDA warning regarding Fosamax and osteonecrosis of the jaw?

The FDA-approved labeling for Fosamax includes a specific section (5.4) on osteonecrosis of the jaw (ONJ), describing its association with bisphosphonates and known risk factors such as invasive dental procedures, cancer, concomitant therapies, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast activity, suppressing bone turnover and impairing the jawbone's ability to repair microdamage. This makes the jaw vulnerable to infections or trauma, leading to ONJ. Multiscale characterization of jawbone tissue has provided insights into this mechanism (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.